Lopinavir/Ritonavir: A Review of Analytical Methodologies for the Drug Substances, Pharmaceutical Formulations and Biological Matrices. (7th November 2022)

• Record Type: Journal Article
• Authors: Velozo, Carolina Trajano; Cabral, Lucio Mendes; Pinto, Eduardo Costa; de Sousa, Valéria Pereira
• Is Part Of: Critical reviews in analytical chemistry. Volume 52:Number 8(2022)
• Page Start: 1846
• Page End: 1862
• Publication Date: 2022-11-07
• Subjects: Analytical methods -- high-performance liquid chromatography -- impurities -- lopinavir -- ritonavir; Chemistry, Analytic -- Periodicals; 543
• DOI: 10.1080/10408347.2021.1920364
• Languages: English
• ISSNs: 1040-8347

Abstract

Abstract: Lopinavir/ritonavir is a potent coformulation of protease inhibitors used against HIV infection. Lopinavir is the main responsible for viral load suppression, whereas ritonavir is a pharmacokinetic enhancer. Both of them have recently gained relevance as candidate drugs against severe coronavirus disease (COVID-19). However, significant beneficial effects were not observed in randomized clinical trials. This review summarizes the main physical-chemical, pharmacodynamic, and pharmacokinetic properties of ritonavir and lopinavir, along with the analytical methodologies applied for biological matrices, pharmaceutical formulations, and stability studies. The work also aimed to provide a comprehensive impurity profile for the combined formulation. Several analytical methods in four different pharmacopeias and 37 articles in literature were evaluated and summarized. Chromatographic methods for these drugs frequently use C8 or C18 stationary phases with acetonitrile and phosphate buffer (with ultraviolet detection) or acetate buffer (with tandem mass spectrometry detection) as the mobile phase. Official compendia methods show disadvantages as extended total run time and complex mobile phases. HPLC tandem-mass spectrometry provided high sensitivity in methodologies applied for human plasma and serum samples, supporting the therapeutic drug monitoring in HIV patients. Ritonavir and lopinavir major degradation products arise in alkaline and acidic environments, respectively. Other non-chromatographic methods were also summarized. Establishing the impurity profile for the combined formulation is challenging due to a large number of impurities reported. Easier and faster analytical methods for impurity assessment are still needed.